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Abstract
Background: Celiac Disease (CD) is both a frequent disease (1:100) and an interesting model of a disease induced by food. It
consists in an immunogenic reaction to wheat gluten and glutenins that has been found to arise in a specific genetic
background; however, this reaction is still only partially understood. Activation of innate immunity by gliadin peptides is an
important component of the early events of the disease. In particular the so-called ‘‘toxic’’ A-gliadin peptide P31-43 induces
several pleiotropic effects including Epidermal Growth Factor Receptor (EGFR)-dependent actin remodelling and
proliferation in cultured cell lines and in enterocytes from CD patients. These effects are mediated by delayed EGFR
degradation and prolonged EGFR activation in endocytic vesicles. In the present study we investigated the effects of gliadin
peptides on the trafficking and maturation of endocytic vesicles.
Methods/Principal Findings: Both P31-43 and the control P57-68 peptide labelled with fluorochromes were found to enter
CaCo-2 cells and interact with the endocytic compartment in pulse and chase, time-lapse, experiments. P31-43 was localised to
vesicles carrying early endocytic markers at time points when P57-68-carrying vesicles mature into late endosomes. In time-lapse
experiments the trafficking of P31-43-labelled vesicles was delayed, regardless of the cargo they were carrying. Furthermore in
celiacenterocytes,fromculturedduodenalbiopsies,P31-43traffickingisdelayedinearlyendocyticvesicles.Asequencesimilarity
search revealed that P31-43 is strikingly similar to Hrs, a key molecule regulating endocytic maturation. A-gliadin peptide P31-43
interfered with Hrs correct localisation to early endosomes as revealed by western blot and immunofluorescence microscopy.
Conclusions: P31-43 and P57-68 enter cells by endocytosis. Only P31-43 localises at the endocytic membranes and delays
vesicle trafficking by interfering with Hrs-mediated maturation to late endosomes in cells and intestinal biopsies.
Consequently, in P31-43-treated cells, Receptor Tyrosin Kinase (RTK) activation is extended. This finding may explain the role
played by gliadin peptides in inducing proliferation and other effects in enterocytes from CD biopsies.
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Introduction
Celiac disease (CD) is characterised by a derangement of both
the adaptive and the innate immune response to gliadin. Some
gliadin peptides that are deamidated by tissue transglutaminase
(e.g., A-gliadin P57-68) bind to HLA DQ2 and/or DQ8 molecules
[1] and induce an adaptive Th1 proinflammatory response. In the
case of the innate immune response, [2] A-gliadin P31-43, which is
not recognised by T cells, [3,4] induces IL15 production, which in
turn is thought to cause expansion of intra epithelial lymphocytes
(IEL) in CD and epithelial apoptosis. [5–6–7] Furthermore, IL15
has been implicated in the increased expression of NKG2D on
lymphocytes. The interaction between the major histocompatibil-
ity complex (MHC) class I chain-related gene A (MICA), and
NKG2D is at least in part responsible for IEL-induced enterocyte
apoptosis and villous atrophy. [8–9]
Many biological activities have been associated with gliadin
peptides in several cell types [10–11–12–13–14] including
reorganisation of actin and increased permeability in the intestinal
epithelium. [15–16] Other effects are specific to celiac tissues. In
untreated celiac patients, P31-43 prevented the restitution of
enterocyte height, which normally occurs after 24–48 h of
culturing mucosal explants with medium alone. [17] P31-43
damaging activity has been demonstrated in organ culture of
treated celiac biopsies, [18] and in in vivo feeding studies. [19]
Similar results have been obtained in vivo on small intestinal and
oral mucosa with the A-gliadin peptide 31–49. [20–21]
It has yet to be established to what extent these properties relate
to the ability of these A-gliadin peptides to activate innate
immunity mechanisms. Virtually nothing is known about the
mechanisms underlying the biological properties of P31-43 or
about the metabolic pathways involved in the activation of innate
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particularly sensitive to these biological activities.
We recently investigated the molecular basis of the non-T cell-
mediated properties of the gliadin peptides most likely to play an
important role in the very early phases of CD, and we found that
P31-43 causes actin alterations and cell proliferation, both of
which depend on activation of the epidermal growth factor
receptor (EGFR), in several cell types, and in the organ culture of
celiac mucosa. [22–23] In this system P31-43 interferes with
EGFR decay and prolongs EGFR activation. We also showed that
P31-43 increases IL15 on the cell surface, by interfering with its
trafficking (MV Barone, unpublished data). These data suggest
that enhancement of EGFR and IL15 signalling may be important
biological contributors to the pathogenesis of CD.
Here we demonstrate that both P31-43 and P57-68 enter CaCo
2 cells and interact with endocytic compartment, but only P31-43
interferes with the endocytic pathway by delaying maturation of
early endosomes to late endosomes. We also show that the P31-43
sequence is similar to hepatocyte growth factor-regulated tyrosine
kinase substrate (Hrs), which is a key protein of endocytic
maturation. [24] P31-43 is localised at the vesicles membranes
and interferes with the correct localisation of Hrs to endocytic
vesicles thus delaying the maturation of early endosomes to late
endosomes. Consequently the activation of EGFR and other
receptors is expanded with multiple effects on various metabolic
pathways and cellular functions.
Materials and Methods
Cell culture, materials and transfections
xCaCo-2 cells were grown in Dulbecco’s Modified Eagle’s
Medium (DMEM) (GIBCO, San Giuliano Milanese, Italy), 10%
foetal calf serum (FCS) (GIBCO, San Giuliano Milanese, Italy), 100
units/ml penicillin-streptomycin (GIBCO, San Giuliano Milanese,
Italy), and 1 mM glutamine. Lipopolysaccharide-(LPS) free syn-
thetic peptides [22] (Inbios, Naples, Italy, .95% pure, MALDI-
TOFF analysis, as expected) were obtained by Ultrasart-D20
filtration (Sartorius AG, Gottingen, Germany). Levels of LPS
were undetectable (,0.20 EU/mg as assessed with a commercial
kit: QCL-1000 kit, Cambrex Corporation, NJ). The P31-43
sequence is LGQQQPFPPQQPY; and the P57-68 sequence is
QLQPFPQPQLPY. The labelled peptides were produced as the
unlabelled peptides. Solutions were used in the following concen-
trations: P31-43-lissamine (liss), P31-43 CY3 and P57-68-liss at 20
micrograms/ml: unlabeled peptides were used as previously
reported, [22] at 70 micrograms/ml; EGF at 100 nanograms/ml;
EGF-Alexa-488 at 20 nanograms/ml (Molecular Probes, San
Giuliano Milanese, Italy); Dextran-Alexa488 (MW 10000) (Molec-
ular Probes, San Giuliano Milanese, Italy) at 0.5 milligrams/ml;
goat polyclonal antibody against EEA1 (C-15) at 2 micrograms/ml
(Santa Cruz, DBA, Milan, Italy); mouse monoclonal antibody
against LAMP2 (H4B4) at 2 micrograms/ml (Santa Cruz, DBA,
Milan, Italy); secondary antibodies anti goat-Alexa-488 conjugated
(Molecular Probes) for EEA1 staining at a ratio of 1:100; and anti
mouse-Alexa 488 conjugated (Molecular Probes) for LAMP2
staining at a ratio of 1:100. Rab5-EGFP and Rab7 EGFP were
kindly provided by Prof. M. Zerial (Max Planck Institute of
Molecular Cell Biology and Genetics, Dresden, Germany) and Hrs-
EGFP was kindly provided by Prof. P.P. Di Fiore (Fondazione
Istituto FIRC di Oncologia Molecolare, Milan, Italy).
Transfections and BrdU incorporation
We used the lipofectamine kit (Invitrogen, San Giuliano
Milanese, Italy) according to the manufacturer’s instructions to
transfect all plasmids (Rab5-EGFP, Rab7-EGFP, Hrs-EGFP and
Hrs-Ha). Briefly, CaCo-2 cells seeded on coverslips for 48 h were
transfected with the plasmids for 16 h. The next day, transfected
cells were pulsed and chased as described below or stained for
Bromodeoxyuridine (BrdU) with a monoclonal antibody (Sigma-
Aldrich, Milan, Italy) and total nuclei were identified by Hoechst
staining. BrdU incorporation was performed as described
elsewhere [22], briefly, CaCo-2 cells seeded on coverslips were
transfected with Hrs-EGFP and serum starved in DMEM 0.1%
foetal calf serum, antibiotics and glutamine for 30–48 h followed
by 24 h treatment with gliadin peptides and/or growth factors.
BrdU (100 mM, Boehringer) was added for one hour before fixing
the samples. The cells fixed with paraformaldehyde and
permeabilised with triton, were stained for BrdU as described
[22] and observed at the miscroscope (Axiophot microscope, Carl
Zeiss MicroImaging, Inc.). Greater than 100 HRS-EGFP positive
cells in several fields were evaluated for BrdU incorporation in
each sample. The number of HRS-EGFP/BrdU positive cells was
expressed as a proportion of the total Hoechst positive nuclei.
Pulse and chase experiments
In pulse and chase experiments, transfected and untransfected
cells were pulsed for 30 minutes at 37uC with a mixture of labelled
and unlabeled peptides to avoid an excess of fluorochromes in the
medium. Overall 20 micrograms/ml of P31-43-liss, P31-43-CY3
and P57-68-liss and 50 micrograms/ml of unlabeled peptides were
used to reach the working concentration of 70 micrograms/ml.
[22] The mixtures of labelled and unlabeled peptides were called
P31-43-liss, P31-43-CY3 and P57-68-liss. After a 30-minutes
treatment with the peptides mixtures (pulse), cells were washed five
times with complete medium to eliminate fluorochrome excess.
Unlabeled peptides (70 micrograms/ml) were added to the cells
and incubation was continued for 3 h at 37uC (chase). Transfected
coverslips were briefly fixed (5 minutes) with paraformaldehyde
3% (Sigma-Aldrich) at room temperature, then mounted.
Untransfected coverslips treated with labelled peptides were
washed and stained for EEA1 and LAMP2.
EEA1 and Lamp staining
CaCo-2 cells seeded on glass coverslips were stained for 1 h at
room temperature with anti-EEA1 or -LAMP2 antibody after
fixation with 3% paraformaldehyde for 5 min at room temperature
and mild permeabilisation with 0.2% Triton (Biorad, Milan, Italy)
for 3 min at room temperature. Secondary antibodies Alexa-488
conjugated (Invitrogen) anti-goat for EEA1 and anti-mouse for
LAMP2 were added to the coverslips for 1 h at room temperature.
Control panels for EEA1 staining with P31-43-liss and non specific
anti-goat antibody together with secondary antibodies Alexa-488
conjugated anti-goat, did not show any cross-excitation of
fluorochromes (Figure S1). Similar results were obtained for Lamp2
and P56-68-liss (not shown). The coverslips were then mounted on
glass slides and observed by confocal microscope (LSM 510 Zeiss).
In total 40 to 50 cells were observed in each sample. Images were
generated with the same confocal microscope. Co-localisation
analysis was performed with AIS Zeiss software. Magnification of
the micrographs was the same for all the figures shown (636
objective) unless stated differently in the legends.
Time-lapse experiments
Cells were seeded on glass-bottom dishes (3 cm in diameter
obtainedfromFalconBectonDickinsonLabware;LaPontdeClaix,
France) to allow live observation, and they were kept in a specially
designed incubator (OXO-lab, Naples, Italy) that controls temper-
ature and CO2. After treatment with gliadin peptides, cells were
P31-43 Localization/Function
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frames were acquired at 30-seconds intervals. The image stack was
analysed with the help of a program that allows to record the tracks
followed by individual particles [25]. Using this methodology the
subsequent positions of each vesicle was identified by the observer,
who, with the help of a pointer on the computer screen, stored the
coordinates in a text file. The program calculated the distance and
direction for each time step; the values shown are the average speed
of each vesicleduring the observationperiod.The list of coordinates
was also used to draw the paths covered by the vesicles, which were
superimposed onto the confocal images.
Co-localisation analysis
Samples were examined with a Zeiss LSM 510 laser scanning
confocal microscope. We used Argon/2 (458, 477, 488, 514
nanometers) and HeNe1 (543 nanometers) excitation lasers, which
were switched on separately to reduce cross-talk of the two
fluorochromes. The green and the red emissions were separated by
a dichroic splitter (FT 560) and filtered (515-to 540-nm band-pass
filter for green and .610-nm long pass filter for red emission). A
threshold was applied to the images to exclude about 99% of the
signal found in control images. The weighted co-localisation
coefficient represents the sum of intensity of co-localising pixels in
channels 1 and 2 as compared to the overall sum of pixel
intensities above threshold. This value could be 0 (no co-
localisation) or 1 (all pixels co-localise). Bright pixels contribute
more than faint pixels. The co-localisation coefficient represents
the weighted co-localisation coefficients of Ch1 (red) with respect
to Ch2 (green) for each experiment. [26–27] The image collection
and exposure times were identical for the two peptides.
Data bank analysis
Swissprot, Trembl and InterPro data banks were searched for
sequences matching peptide P31-43 and P57-68 by using Blast and
FastA. Sequence alignment was performed by using ClustalW and
visualized by PrettyPlot from the EMBOSS suite.
Immunoblotting and subcellular fractionation
Near-confluent Caco2 cells in a 90-mm dish were incubated
with EGF and P31-43 at various times, after homogenization
Figure 1. Vesicles interacting with P31-43-liss are early endocytic vesicles after a 3 h chase. In CaCo-2 cells, both after 30 minutes of pulse
and 3 hours of chase with P31-43-liss (red), the peptide interacted with vesicles that are positive for EEA1 (green staining, top and middle panel). P31-
43-liss did not co- localise with LAMP2-positive vesicles (green staining, bottom panel) after 3 hours of chase. A merge of the red and green panels of
the EEA1 or LAMP2 and P31-43-liss or P57-68-liss staining is shown, the yellow/orange colour indicates co- localisation. The zoom panels represent a
digital 46enlargement of the region highlighted by white lines in the merge panels. The co- localisation coefficient was calculated as reported in the
‘‘Methods’’ section. The results are representative of four independent experiments.
doi:10.1371/journal.pone.0012246.g001
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phosphatase and protease inhibitors) the nuclear fraction was
eliminated by centrifugation. The soluble cytosolic and the
membrane fraction were obtained by ultracentrifugation.
Electrophoresis and immunoblotting were performed as de-
scribed elsewhere. [22] Briefly the proteins of the soluble
cytosolic and the membrane fractions were separated by SDS-
PAGE and incubated with anti-Hrs mouse monoclonal
antibody (Alexis, Vinci-Biochem, Florence, Italy) or anti-EGFR
rabbit polyclonal antibody (Cell Signaling Celbio, Milan Italy)
or anti-tubulin mouse monoclonal antibody (SIGMA-Aldrich,
Milan, Italy). Densitometric analysis was performed as before.
[22]
Organ culture studies
All biopsies were treated as previously described. [22] To
examine the entry of P31-43-CY3 into cells, we cultured three
intestinal biopsies from untreated celiac patients in the active
phase of the disease and three from control subjects affected by
gastro-oesophageal reflux for 3 h with P31-43-CY3 (20 micro-
grams/ml) and with unlabelled P31-43 (50 micrograms/ml). The
samples were then washed, and chased for 24 h. Three samples
from CD patients and three from controls were harvested after a
3-h pulse; three other samples from patients and controls were
harvested after 24 h of chase. All samples were prepared for cryo-
sectioning. Air-dried, 5 microns sections were stained for EEA1
and analysed with a confocal microscope. Anti EEA1 antibody
was applied to the sections for 1 hour at room temperature and
secondary antibody anti goat Alexa-488 conjugated was applied to
the sections for 1 h at room temperature in a dark chamber. The
protocol of the study was approved by the Ethical Committee of
the University ‘‘Federico II’’, Naples, Italy (Etical approval code:
C.E. n. 230/05).
Results
Different vesicle subpopulations carry P31-43 or P57-68
peptides
Peptides P31-43 and P57-68 enter the cells and interact with
vesicular compartment. We used markers of the endocytic
pathway to identify the vesicular compartment that interacts with
P31-43-liss and P57-68-liss.
Figure 2. Vesicles interacting with P57-68-liss are late endocytic vesicles after a 3 h chase. At 30 minutes pulse, P57-68-liss co- localised
with EEA1-positive vesicles (top panel); however after 3 hours of chase P57-68-liss no longer co- localised with EEA1-positive vesicles (middle panel).
After 3 hours of chase, P57-68-liss co- localised with LAMP2-positive vesicles (bottom panel). Merge of the red and green panels of the EEA1 or
LAMP2 and P31-43-liss or P57-68-liss staining is shown, yellow/orange colour indicates co- localisation. The zoom panels represent a digital 46
enlargement of the region highlighted by white lines in the merge panels. The co- localisation coefficient was calculated as reported under
‘‘Methods’’. The results are representative of four independent experiments.
doi:10.1371/journal.pone.0012246.g002
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markers of early endocytosis. CaCo-2 cells treated with labelled
peptides for 30 minutes (pulse) and 3 hours (chase) were stained
with anti-EEA1 antibodies to identify early endocytic vesicles.
Both peptides co-localised with EEA1-positive vesicles at 30
minutes (Figure 1 and 2), but only P31-43-liss-carrying vesicles
were EEA1-positive after 3 hours of chase. Similar results were
obtained with CaCo-2 cells overexpressing Rab 5-EGFP protein
(not shown). Normal endocytic maturation requires the progres-
sion from early vesicles to late vesicles. We used the late endocytic
markers LAMP2 (Figure 1) and Rab7-EGFP (not shown) to
investigate the progression of endocytosis. CaCo-2 cells treated
with labelled peptides for a 30-minutes pulse and a 3-hours chase
were stained with anti-LAMP2 antibodies to identify late
endocytic vesicles. Neither P31-43-liss nor P57-68-liss peptides
co-localised with LAMP2-positive vesicles at 30 minutes (not
shown). Only P57-68-liss-carrying vesicles were LAMP2-positive
after 3 hours of chase (Figure 1 and 2). Taken together, these
observations indicate that P31-43-containing vesicles, but not P57-
68-containing vesicles are impaired in their maturation from early
to late endosomes.
P31-43-liss-carrying vesicles move more slowly than P57-
68-liss-carrying vesicles
To test the hypothesis that P31-43 could interfere with vesicle
movements, we examined living cells labelled with the two
peptides. The paths followed by individual vesicles were recorded
after treatment with P31-43-liss and P57-68-liss peptides (Movie
S1 and Movie S2). The movement of peptide-carrying vesicles was
analysed for 10 minutes immediately after a 30-minutes pulse and
after a 3-hours chase (Figure 3); data are reported as the average of
three independent experiments. P57-68 vesicles had longer
trajectories in pulse (0.4460.009 microns/10 minutes) and chase
(0.5160.095 microns/10 minutes) experiments. P31-43-liss-inter-
acting vesicles moved much less under both conditions
(0.2860.035 microns/10 minutes in pulse and 0.2960.021
microns/10 minutes in chase experiments). Directionality of the
endosome movements seems not to be affected by P31-43.
P31-43-induced delay of endocytic vesicle dynamics is
unrelated to their cargo
To determine whether P31-43 is selectively directed to a specific
population of slower vesicles or is able to delay endocytosis of
vesicles where it is directed, we loaded CaCo-2 cells with Alexa-
488 labelled dextran, a compound that is readily endocytosed in
the cells, and EGF-Alexa, which normally enters the cells bound to
the EGFR. CaCo-2 cells were pulsed for 30 minutes and chased
for 3 hours with dextran-Alexa-488 alone or combined with P31-
43-liss or P57-68 liss and then observed for 10 minutes in time-
lapse microscopy. In experiments with dextran-Alexa-488 and
P31-43-liss, most vesicles carry both fluorochromes, and are slower
than vesicles carrying dextran alone or combined with P57-68
(Figure 4A), suggesting that the peptide, rather than the contents of
the endocytic vesicle, is responsible for slower vesicle movement
and delayed endocytosis.
We similarly investigated whether P31-43, which is known to
interfere with EGF-carrying vesicles, [22] also affects the dynamics
of EGF-Alexa-488-containing vesicles. Time-lapse analysis showed
that P31-43-liss, unlike P57-68, delays EGF-Alexa-488-carrying
vesicles (Figure. 4B). The fact that the peptide can delay endocytic
vesicles carrying dextran or EGF strongly supports the hypothesis
that the peptide is able to delay early endocytotic vesicles,
Figure 3. P31-43-liss-carrying vesicles are slower than P57-68-liss-carrying vesicles. Statistical analysis of three experiments performed
resulted as follows: live CaCo2 cells pulsed for 30 minutes and chased for 3 hours with lissamine-labelled peptides were used for time-lapse
experiments in which we acquired images every 30 seconds for 10 minutes at the indicated times. The image stacks were assembled to produce a
video of vesicles dynamics. In each experiment, the position of at least 25 vesicles per cell was recorded and reconstructed to mark the trajectories of
each vesicle during the observation time. The speed of vesicles was calculated by averaging the trajectories produced in 10 minutes at the indicated
times. Bars represent mean and standard deviation. Asterisks indicate P,0.05 (Student’s t-test). P31-43 carrying vesicles both at 30 minutes of pulse
and 3 hours of chase are statistically significantly slower than P57-68 carrying vesicles.
doi:10.1371/journal.pone.0012246.g003
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P31-43 on the endocytic pathway, in the case of EGFR, as we
have shown previously, [22] result in an extension of the activation
period of this receptor, which accounts for the stimulation of
EGFR dependent pathways. [22] This mechanism is likely to be
responsible also for activation of other receptors sharing the same
endocytic pathway.
P31-43 shares sequence similarity with Hrs, a key
molecule in the maturation of endocytic vesicles
We carried out a FASTA search on the SWISSPROT database
using gliadin peptide 31–43 as query sequence to look for
endogenous proteins with a similar primary structure. The search
returned, for both P31-43 and 31–49, a match with amino acids
719–731 of human Hrs, a protein with no known relationship to
gliadin. The degree of similarity is high, with a better score and e-
value than many matches with gliadin family proteins. Figure 5A
shows the alignment of P31-43 with human Hrs and with Hrs
from mouse, rat and Drosophila melanogaster. Of the 13 residues in
the peptide, 7 are identical and 2 similar to the corresponding
residues of human Hrs, the only major difference being the
peptide N-terminal leucine instead of the consensus proline. The
similarity area maps within a proline/glutamine-rich domain of
Hrs and is conserved better than the surrounding area among Hrs
orthologs. This finding is interesting because Hrs is localised both
in the cytosol and in endocytic vesicles and is involved in the
transport of EGFR, PDGFR and other receptor-containing early
endosomes to lysosomes. [24–28] We carried out the same data
bank search using the gliadin peptide P57-68, and failed to find
any relevant similarity with Hrs or other human proteins.
P31-43 is localised at the level of the membranes in
endocytic vesicles
We next investigated the sub-cellular localisation of gliadin
peptides P31-43 and P57-68. P31-43 has been described by
electron microscopy to be localized at the level of endocytic
membranes. [29] When cells are transfected with Hrs, enlarged
early endosomes are formed due to increased fusion; [30]
furthermore detection of membrane vesicles by confocal immu-
nofluorescence microscopy is facilitated. We then overexpressed
Hrs-EGFP in CaCo2 cells for 48 h to obtain larger endosomes.
P31-43 or P57-68 were added for 15 minutes and then the
experiment was stopped. In Figure 5B one of these experiments is
shown. As expected large endosomes can be seen with Hrs-EGFP
Figure 4. P31-43 delays endocytosis regardless of vesicles cargo. A) Dextran-Alexa-488-carrying vesicles moved faster than dextran-Alexa-
488- and P31-43-liss-carrying vesicles. Live CaCo2 cells were pulsed for 30 minutes with dextran-Alexa-488 with and without P31-43-liss or P57-68-liss
then chased for 3 hours in time lapse experiments. Only the 30 minutes pulse experiments are shown. The histogram shows the statistical analysis of
three experiments. We calculated the speed of vesicles by averaging the trajectories produced in 10 minutes as in Figure 2. Bars represent mean and
standard deviation. P31-43-liss and Dextran-Alexa-488 co-localised in the vesicular compartment. B) Live CaCo2 were pulsed for 30 minutes and
chased for 3 hours (not shown) with EGF-Alexa-488 conjugated with and without P31-43-liss or P57-68-liss. Only the 30 minutes pulse experiments
are shown. The histogram on the right side shows the statistical analysis of three experiments. We calculated the speed of vesicles by averaging the
trajectories produced in 10 minutes as in Figure 2. Bars represent mean and standard deviation. P31-43-liss co- localises with EGF-Alexa 488 in the
vesicular compartment. Asterisk indicates P,0.05 (student’s t-test). The results show that P31-43 carrying vesicles are slower regardless of the cargo
they are carrying.
doi:10.1371/journal.pone.0012246.g004
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not P57-68 co-localises with Hrs on the vesicles membranes,
indicating that the two peptides may have different ways of
entering the same endocytic vesicles.
P31-43, but not P57-68, competes with Hrs localisation in
endocytic vesicles
Because there is a close sequence similarity between P31-43 and
Hrs within a region that is important for the localisation of Hrs to
the vesicle membrane, we evaluated whether the peptide could
interfere with Hrs localisation to the vesicles. To this aim, we
treated CaCo-2 cells with P31-43 or EGF, and then separated
cytosolic and membrane bound proteins by ultracentrifugation to
quantify the amount of endogenous Hrs present in each
compartment. [30] P31-43 resulted in an increase in the amount
of Hrs in the cytosolic fraction, which reached a maximum 3 h
after treatment (Figure. 6A,B), whereas the amount of Hrs was
decreased in the membrane fraction. This effect was unrelated to
the enhanced EGF pathway because EGF treatment alone did not
affect Hrs concentration in either compartment, in agreement with
previous results. [30] The Hrs concentration was normalised to a
control protein stained on the same blot, namely, tubulin in the
cytosolic fraction and EGFR in the membrane fraction. [30] We
used tubulin and EGFR because they selectively localise to the
cytosolic and membrane fractions and their concentration is not
affected by P31-43 treatment.
The results of confocal analysis are in agreement with the results
of the western blot experiment. In fact, 24 h after transfection of
the Hrs-EGFP fusion protein into CaCo-2 cells, fluorescence was
mostly associated with vesicles, whereas 3 h treatment with P31-43
resulted in diffused cytoplasmic staining (Figure 6C). Hrs remained
associated to vesicles in the control peptide P57-68 (Figure 6C).
Hrs overexpression prevents entry into the cell cycle
induced by P31-43
Evidence suggests that gliadin peptides affect the cell cycle by
delaying receptor inactivation. [22] Should this effect be due to
competition of the gliadin peptide P31-43 with Hrs, large over
Figure 5. P31-43 is similar to Hrs and is localised at the membrane vesicles. A) Multiple alignments of gliadin peptides P31-43 and P31-49
are shown, with Hrs from mouse, rat, human and Drosophila. Numbers on the right side of the figure represent the terminal amino acid position of
each sequence shown. Of the 13 residues in P31-43, 7 are identical (red) and 2 similar (green) to the corresponding residues of human Hrs. B)
Enlarged vesicles visible by multiple digital enlargement (86) of the cytosol of a single cell. Hrs-EGFP was transfected for 48 hours in CaCo2 cells. P31-
43 or P57-68 was added for 15 minutes. On the right side is the profile of the red and green channels along the white arrows that run across a single
vesicle in the figure. The figure is representative of four similar independent experiments. Enlargement of the endocytic vesicles allow the
observation of the vesicle membrane. In a short time (15 minutes) only P31-43 but not P57-68 co- localises with Hrs-EGFP at the vesicle membrane.
doi:10.1371/journal.pone.0012246.g005
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therefore evaluated whether Hrs can compete with the effects
induced by P31-43 on the cell cycle. As shown in Figure 7, CaCo-2
cells over expressing Hrs were stimulated to proliferate by adding
EGF, P57-68 or P31-43. Under these conditions, EGF stimulation
greatly increased BrdU incorporation in Hrs-transfected and
untransfected CaCo-2 cells (Hrs=66.25%69.53%; No Hrs=
68.99%67). As expected from a previous study, [22] P31-43
induced proliferation of non-Hrs-expressing CaCo-2 cells, with a
BrdU incorporation of 51%62% that decreased to 22.8%68.4%
in Hrs-expressing CaCo-2 cells. P57-68 did not induce prolifer-
ation. These data indicate that Hrs can compete with the effects
exerted by P31-43 on cell proliferation.
In cultured small intestine samples from biopsies, P31-43
enters the enterocytes and interacts with early endocytic
vesicles
We investigated whether P31-43 enters the cell and traced its
localisation in intestinal biopsies from CD patients. For this set of
experiments, we labelled P31-43 with CY3, a fluorochrome that is
excited at 553 nanometers and emits at 575 nanometers. Intestinal
biopsies were obtained from patients with CD and control
subjects, kept in culture, and pulsed for 3 h with P31-43-CY3
(Figure 8A and B). In all biopsies, after 3 h pulse, peptide P31-43-
CY3 was seen in epithelial cells, both in the crypts and in the villi
(not shown) where it interacted with vesicles at the apical portion
of the cells. Staining with anti EEA1 antibodies shows that the
vesicles interacting with P31-43-CY3 are early endocytic vesicles.
The overlay panels in Figure 8A and B show co- localisation of
P31-43-CY3 and EEA1 in controls subjects and in patients with
CD in the active phase of the disease. After 24 h chase, P31-43-
CY3 was seen only in cells from CD patients. In this case the
labelled peptide also interacted with the vesicular compartment
and co-localised with EEA1 (Figure 8B). In normal controls, P31-
43-CY3 entered the cells and interacted with EEA1-positive
vesicles after a 3 h pulse, but the peptide was no longer seen after a
24-hours chase (Figure 8A). This indicates that, in healthy
controls, this peptide is readily processed by the vesicular
compartment. In the celiac environment, in which the peptide
interacts with the vesicular compartment, P31-43 is delayed in
early endocytic vesicles also at 24-hours chase.
Discussion
In this paper we demonstrate that A gliadin peptides P31-43
and P57-68 enter CaCo2 cells. P31-43 localises on the endocytic
membranes and delays vesicle trafficking by interfering with Hrs-
Figure 6. P31-43 competes with Hrs localisation to the endocytic vesicles. A) Western blot analysis of endogenous Hrs after separation by
ultracentrifugation of cytosolic and membrane proteins. EGFR was used as a control for membrane fraction and tubulin as a control for cytosol. The
last line on the right is a lysate of CaCo-2 cells transfected with Hrs as a size control for the protein. The results are representative of three
independent experiments. B) Densitometric analysis. The Hrs concentration was normalised to a control protein, namely tubulin in the cytosolic
fraction and EGFR in the membrane fraction. Mean and SD of three independent experiments is shown. Asterisk indicates P,0.05 (student’s t-test).
After P31-43 treatment, Hrs increases in the cytosolic fraction and decreases in the membrane fraction in comparison to the not treated sample in a
statistically significant way. C) Confocal analysis of CaCo-2 cells transfected for 24 h with Hrs-EGFP, not treated and treated with P57-68 and P31-43
for the last 3 h of transfection. The results are representative of four independent experiments.
doi:10.1371/journal.pone.0012246.g006
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Consequently, EGFR and possibly other receptors activation is
extended with multiple effects on various metabolic pathways and
cellular functions.
Although little is known about the processing of gliadin
peptides, there is evidence that they enter enterocytes. [31–32–
33]. Recently two papers [29–34] have described entrance and
localization of P31-43 and P57-68 gliadin peptides, one localising
P31-43 to the level of early endocytic vesicles using electro-
microscopy, (which is consistent with our findings), and the other
localising it to the level of the late vesicles using light microscopy of
biotinylated peptides. Zimmer et al have shown, that P31-43,
which is found in early vesicles, is not presented to stimulate gluten
sensitive T-cells, in contrast P57-68 is found in late vesicles and
can be presented in this manner. [29] The results of our
experiments show that both P31-43 and P57-68 enter CaCo-2
cells and interact with the vesicular compartment. Their entrance
is an active process that requires a temperature of 37C and Ca++
in the media. Methyl-Beta-Cyclodextrin, an inhibitor of endocy-
tosis, prevents the entrance of both peptides indicating that they
enter the cells by endocytosis. [35–36]
We mapped the distribution of P31-43 and P57-68 along the
endocytic pathway using markers of early endosomes (EEA1;
RAB5-EGFP) and late endosomes (LAMP 2; RAB7-EGFP). P57-
68 could progress from the early, EEA1 positive, endocytic
compartment to the late, LAMP2 positive, compartment after a
3 h chase. P31-43 instead interacted both at 30 minutes and
3 hours with the early endocytic compartment. Vesicular dynamic
correlates with proper maturation of early endocytic vesicles [30]
and can be altered by proline/glutamine rich proteins such as
Huntingtin. [37] We therefore, investigated the motility of vesicles
carrying P31-43-liss and P57-68-liss. Live observation of cells
treated with fluorescent peptides (time lapse) indicated that the
P31-43-carrying vesicles are slower than those carrying P57-68 at
both 30 minutes and 3 hours. Taken together, these results suggest
that P31-43 remains in the early endocytic vesicles, thereby
delaying maturation of these vesicles into late endosomes by
affecting endocytic motility. Moreover P31-43, but not P57-68 was
able to delay endocytic vesicles containing EGF-Alexa [22] and
dextran indicating that P31-43 interferes with vesicular dynamics
no matter what cargo they are carrying. Consequently EGFR and
other receptors can stay longer activated. There is in fact
compelling evidence that endocytic membrane trafficking regu-
lates signalling by extra cellular ligands. [38]
The delay of decay of the EGF receptor may have different
consequences in different cell types because it affects several
pathways and different functions (cell reproduction and survival,
permeability, motility, endocytosis etc.) (Figure 9). [39–40]. We
previously showed that gliadin peptides, and in particular P31-43,
induce actin rearrangements and cell proliferation in various cell
types, thereby mimicking the effect of EGF. Peptide 31–43 induces
phosphorylation of EGFR and of the downstream effector
signalling molecule ERK [22] which indicates activation of the
EGFR pathway. Enhancement of the EGF pathway by gliadin
and P31-43 is due to delayed inactivation of EGFR. [22].
It is likely that endocytic delay could also affect the innate
immune response and cytokine metabolism. We have shown (MV
Barone, unpublished data) that in CaCo2 cells gliadin peptide
P31-43 can enhance the recycling endocytic compartment. As a
consequence of this process, more transferrin receptor and IL15
accumulates on the cell surface. Recently, the recycling transferrin
receptor has been implicated in the pathogenesis of CD. In fact,
transferrin receptors are increased in celiac intestine and also
function as IgA receptors that retrotranscytose P31-49 linked to
IgA. [41] Taken together these data suggest that an important
pathogenetic event in CD is the interference of gliadin peptide
P31-43 with the endocytic compartment.
A data bank search using P31-43 as the query sequence,
revealed strong sequence similarity with a region of Hrs, which is
an important regulator of endocytic trafficking. Hrs is the main
coordinator of endocytosis and signalling. It is part of a large
complex, located to early endocytic vesicles and the multivesicular
body, that is involved in the ubiquitination of proteins destined to
lysosomes. It can be phosphorylated in cells treated with growth
Figure 7. Hrs competes with the effects of P31-43 on the G0 .S transition. Bromodeoxyuridine (BrdU) incorporation of CaCo-2 cells
transfected or not with Hrs-EGFP cDNA and treated as indicated 24 h after transfection. The bars represent the fraction of BrdU incorporating cells as
a percent of total cells and are the mean 6 SD of three independent experiments. Asterisks indicate P,0.05 (Student’s t-test) with respect to the 0,1%
FCS. These results indicate that Hrs compete with the effects exerted by P31-43 on cell proliferation.
doi:10.1371/journal.pone.0012246.g007
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translational modifications are needed for efficient sorting by Hrs
of ubiquitinated membrane proteins to the degradation pathway.
In cells where Hrs has been silenced, mutated or dislocated from
the endosomes, EGFR and other receptor tyrosine kinases stay
activated longer [42] and are recycled back to the cell surface. [43]
The sequence similarity between gliadin peptide P31-43 and
Hrs involves a small area of the proline/glutamine-rich domain of
the latter. Although gliadin is a well known proline/glutamine-rich
protein, the homology of P31-43 with this Hrs domain is specific
because the rest of the gliadin proline/glutamine-rich sequence
does not share the same degree of similarity with Hrs. Moreover,
P57-68, another gliadin peptide with a similar amino acid
composition, does not produce the same effects in cells. This
Hrs domain, at its COOH end, contains the clathrin-binding
domain that brings clathrin to clathrin coated vesicles, [27] and is
one of the domains needed to localise Hrs to the vesicle
membranes. [44–45–46]
We have demonstrated in Hrs-EGFP transfected CaCo2 cells
that P31-43, but not P57-68 co-localises with Hrs on the membrane
of endocytic vesicles after 15 minutes of treatment, suggesting that
the two peptides may have a different route to enter endocytic
vesicles. Up to now no receptor has been found for P31-43 uptake.
(Barone et al. unpublished results). Vilasi et al. [47] have proposed
an alternative possibility investigating the interaction of the gliadin
peptides with a very simple model of lipids micellae. They showed
that P31-43 but not P57-68 can directly interact with the micellae, a
good indication that it is possible for P31-43 to travel through the
membranes and possibly reach the HRS molecules on the surface of
the vesicles. We next evaluated whether P31-43 could interfere with
Hrs localisation to the endocytic vesicles.
Western blot analysis of proteins extracted from the cell cytosol
and membranes, together with immunofluorescence, showed that
P31-43 treatment for 3 h, moved HRS from the vesicles to the
cytosol. Furthermore, if P31-43 interferes with Hrs localization, it
follows that a large excess of Hrs should prevent the proliferative
activity of the gliadin peptide on cells. In fact, over expression of
Hrs-EGFP prevented the effect of P31-43 on CaCo-2 prolifera-
tion. Taken together these results suggest that P31-43 interferes
with Hrs-mediated maturation of early endosomes.
Figure 8. After a 24-h chase, gliadin peptide P31-43-CY3 is still present in epithelial cells of crypts of celiac disease patients, but not
of controls. Intestinal biopsies from control subjects (A) and celiac disease patients on a gluten-containing diet (B) were cultivated with CY3-labelled
P31-43 for 3 h and then chased for 24 h as indicated. Thin sections of the cultivated biopsies were then stained with anti-EEA1 antibodies. In control
sections (A), P31-43-CY3 was visible only after 3-h pulse, but not after a 24 h chase. In the section of a celiac disease patient, P31-43-CY3 was present
at both 3 h and 24 h in the epithelial cells of crypts. Overlay panels show that in cultivated biopsies from celiac patients at any time and in controls
only at 3 h pulse, the P31-43 peptide co- localised with EEA1. White arrows indicates localisation of peptide in the early endocytic vesicles.
Representative results from 3 independent experiments are shown.
doi:10.1371/journal.pone.0012246.g008
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biopsies from CD patients and controls using pulse and chase
experiments. We show that P31-43 enters the enterocytes of
cultured intestinal biopsies and localise, after a 3 h pulse, in early
endocytic vesicles of enterocytes of intestinal biopsies from normal
control subjects and non-treated celiac patients. However, after a
24-h chase, the peptide was still in the early endosomes of celiac
enterocytes, but not in those of controls. This suggests that celiac
patients are particularly susceptible to the effect of P31-43. We
previously reported that endocytosis of EGF is delayed in
enterocytes of atrophic celiac mucosa cultured in vitro with P31-
43. [22] In the same context, P31-43 increased proliferation of
crypts enterocytes – an effect that was prevented by EGFR
inhibitors. [22]. Similar to the effects we observed in CaCo-2 cells,
P31-43 probably delayed maturation of early endocytic vesicles
also in cultured biopsies. This process prolongs EGFR activation
and culminates in increased EGFR-dependent proliferation of
crypt enterocytes as we have previously shown. [22] These
observations suggest that the EGF pathway plays a central role in
initiating and maintaining the high proliferation rates observed in
the crypts of celiac patients. [48–49] This finding explains at least
in part the role played by gliadin in remodelling of the celiac
mucosa.
From a general point of view it is interesting to note that
peptides from a very common alimentary protein, the gliadin, can
have several metabolic effects due to the interference with
important cellular functions, such as those regulated by the
endocytic pathway. It remains to be established why P31-43 has a
peculiar effect on the celiac intestinal mucosa. Celiac patients may
have an alteration of the endocytic pathway (or some other related
metabolic pathway) that renders cells more sensitive to the effect of
P31-43 on endocytic maturation.
Supporting Information
Figure S1 Control panel for EEA1 staining did not show any
cross-excitation of fluorocromes: CaCo-2 cells, after 30 minutes
pulse with P31-43-liss (red), were fixed permibilised and stained
with an isotype matched primary antibody and anti-goat
secondary antibodies Alexa-488 conjugated (green). The control
shows that there isn’t any cross-excitation of fluorocromes between
the Alexa-488 conjugated secondary antibody and the lissamine
linked to the peptide. Merge of the red and green panels is shown.
The results are representative of 4 independent experiments.
Found at: doi:10.1371/journal.pone.0012246.s001 (2.37 MB
TIF)
Movie S1 In Materials and Methods of the text.
Found at: doi:10.1371/journal.pone.0012246.s002 (1.88 MB AVI)
Movie S2 In Materials and Methods of the text.
Found at: doi:10.1371/journal.pone.0012246.s003 (2.42 MB AVI)
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